Zai Lab (NASDAQ:ZLAB) Posts Earnings Results, Beats Estimates By $0.22 EPS

Zai Lab (NASDAQ:ZLAB) released its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.22, Zacks reports. Zai Lab had a negative return on equity of 26.42% and a negative net margin of 41.86%.The business had revenue of $106.31 million during the quarter, compared to analysts’ expectations of $103.87 million.

Here are the key takeaways from Zai Lab’s conference call:

• Positive Sentiment: Zai Lab reported second-quarter net product revenue of $105.8 million, up 11% sequentially, while maintaining a commercially profitable business. Management expects KarXT, potential NRDL inclusions, and continued demand for key brands to support meaningful growth in 2027.
• Positive Sentiment: The DLL3 ADC zoci is advancing rapidly, with a global Phase III second-line small-cell lung cancer trial expected to complete enrollment in the first half of 2027 and a potential U.S. accelerated-approval submission later that year. The company also plans a first-line, chemo-sparing Phase III combination study and expects three registrational programs by year-end.
• Positive Sentiment: ZL-1503, a long-acting IL-13/IL-31 bispecific for atopic dermatitis, is expected to generate initial human pharmacokinetic, pharmacodynamic, safety, and immunogenicity data in the second half of 2026. Zai believes its potential for durable itch reduction, skin clearance, and less frequent dosing could differentiate it in a competitive market.
• Negative Sentiment: Management did not reaffirm its prior goal of reaching overall profitability by the end of 2025, instead indicating that profitability will develop over time as revenue grows and global assets advance. Continued investment in multiple global programs means operating expenses are expected to remain broadly stable through the rest of 2026.
• Neutral Sentiment: The company ended the quarter with $717.5 million in cash and is prioritizing spending on its highest-value programs while streamlining operations and expanding AI use across functions. Additional pipeline catalysts include initial ZL-6201 data expected in the first half of 2027 and an IND filing for the MUC17 T-cell engager ZL-1311 by year-end.

Zai Lab Stock Up 11.7%

Shares of Zai Lab stock opened at $23.32 on Friday. Zai Lab has a 12-month low of $15.96 and a 12-month high of $36.77. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -13.64 and a beta of 0.78. The firm’s 50-day moving average price is $18.75 and its two-hundred day moving average price is $19.25.

Wall Street Analysts Forecast Growth

ZLAB has been the subject of a number of recent research reports. Citigroup boosted their target price on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Zacks Research raised shares of Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zai Lab presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.20.

Insiders Place Their Bets

In other news, CFO Yajing Chen sold 2,264 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $17.46, for a total transaction of $39,529.44. Following the completion of the transaction, the chief financial officer owned 35,691 shares of the company’s stock, valued at approximately $623,164.86. The trade was a 5.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William Lis sold 7,040 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $18.09, for a total value of $127,353.60. Following the sale, the director owned 50,437 shares of the company’s stock, valued at approximately $912,405.33. This represents a 12.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 90,873 shares of company stock worth $1,730,096 over the last three months. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada grew its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.